Hopperptan

Mechanism

Pharmacological Group

Selective non-peptide antagonist of the vasopressin V₂ receptor (antidiuretic hormone - ADH).

Mechanism of Action

Tolvaptan binds competitively and with high affinity to the vasopressin type 2 receptor (V₂) on the basolateral membrane of the principal cells of the Collecting Duct. By blocking intracellular signaling dependent on Gs protein and cyclic adenosine monophosphate (cAMP):

1. Prevents the phosphorylation and subsequent translocation of the vesicles containing the water channels Aquaporin-2 (AQP2) to the apical membrane.
2. Directly blocks the reabsorption of free water mediated by the osmotic gradient.

This promotes aquaresis (selective urinary elimination of electrolyte-free water), raising plasma sodium levels in a controlled manner without directly altering the net excretion of sodium or potassium.

Pharmacokinetics

Key Pharmacokinetics

• Administration: Orally only.
• Bioavailability: 40% (increases with fatty foods).
• Protein binding: Extremely high (>99%), selectively bound to plasma proteins.
• Metabolism: Metabolized almost entirely in the liver through the cytochrome CYP3A4 pathway. It has inactive metabolites.
• Excretion: Mainly fecal (>60%) as metabolites; Less than 1% is eliminated unchanged through the kidneys.
• Half-life: ~12 hours.

Indicators and dose

Clinical Indications

• Clinically significant hypervolemic or euvolemic hyponatremia (serum sodium < 125 mEq/L): Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), or associated with decompensated congestive heart failure (when fluid restriction alone has failed).
• Autosomal Dominant Polycystic Kidney Disease (ARPD): To slow the progression of cyst growth and the development of kidney failure (TEMPO 3:4 and REPRISE pivotal clinical studies).

Dosage and Settings

• Hyponatremia (SIADH / IC): Start with 15 mg orally once a day. It can be doubled to 30 mg or a maximum of 60 mg daily depending on response, always monitoring the rate of sodium rise. Do not maintain treatment for more than 30 continuous days due to liver risk.
• ERPAD (Polycystic Disease): Regimen in two asymmetric divided doses to ensure receptor blockade for 24 hours (e.g. 45 mg in the morning upon awakening and 15 mg 8 hours later), gradually escalating according to tolerance up to a maximum of 90 mg/30 mg daily.
• Renal adjustment: Does not require dose adjustment in patients with CrCl > 10 mL/min, but is not clinically effective and should be avoided in CrCl < 10 mL/min.

Security

Danger of Pontine Myelinolysis and Hepatotoxicity Alert

The main risk of tolvaptan during the correction of hyponatremia is osmotic demyelination syndrome (pontine myelinolysis) due to an excessively rapid rate of increase in serum sodium. An increase of 8 to 12 mEq/L in 24 hours, or 18 mEq/L in 48 hours, should not be exceeded. Requires serum sodium controls every 6-8 hours after onset. Additionally, tolvaptan presents a warning of severe hepatotoxicity with marked elevation of transaminases if used chronically (associated with the dose required in polycystic kidney disease). Rigorous monthly monitoring of transaminases is required and its prescription is limited under specific pharmacovigilance programs.

Contraindications

• Absolute: Urgent need to raise serum sodium immediately to reverse severe neurological symptoms (in such cases, use 3% hypertonic saline); inability to sense thirst or obtain free water on one's own (risk of severe dehydrating hypernatremia); established decompensated hypovolemia; concomitant use with strong CYP3A4 inhibitors; anuria.

Adverse Effects (ADR)

• Very common: Intense thirst (polydipsia), marked dry mouth, severe polyuria with frequency.
• Common: Hypernatremia due to aquaretic dehydration, orthostatic dizziness, transient elevation of plasma uric acid, nausea.
• Serious: Idiosyncratic toxic liver injury (with ALT/AST elevations > 3 times the normal limit in 4.4% of patients with polycystic kidney disease).

Interactions

• Potent CYP3A4 inhibitors (e.g. Clarithromycin, Itraconazole, Ketoconazole): Massively increase tolvaptan levels, increasing the risk of uncontrollable sodium correction. Absolutely contraindicated.
• Agents that raise Serum Sodium (e.g. Hypertonic Saline): Extreme risk of hypervelocity correction and osmotic demyelination.

Pregnancy and Breastfeeding

Category C. Demonstrated embryotoxicity and fetal malformations in animal models at high exposure doses. Not recommended during pregnancy or in women of childbearing age who do not use effective contraception.